| BP0301-50MG
| InVivoPlus human IgG2 isotype control
| 50 mg
| BioXCell
|
|
| Human
|
| Request Quotation
| Request
|
| BP0045-100MG
| InVivoPlus anti-mouse IL-4
| 100 mg
| BioXCell
| in vivo IL-4 neutralization, in vitro IL-4 neutral
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0308-5MG
| InVivoPlus anti-rat CD4
| 5 mg
| BioXCell
| in vivo CD4+ T cell depletion, Flow cytometry
|
| Mouse
| Rat
| Request Quotation
| Request
|
| BP0057-100MG
| InVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-?
| 100 mg
| BioXCell
| in vivo TGF? neutralization, in vitro TGF? neutral
|
| Mouse
| Goat, Dog, Hamster, Human, Monkey, Mouse, Rat
| Request Quotation
| Request
|
| BE0407-100MG
| InVivoMAb anti-human Fy3
| 100 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BE0393-50MG
| InVivoMAb anti-mouse myeloperoxidase (MPO)
| 50 mg
| BioXCell
| in vivo administration, in vitro administration, I
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0213-100MG
| InVivoPlus anti-mouse CSF1R (CD115)
| 100 mg
| BioXCell
| in vivo macrophage depletion, in vitro CSF1R neutr
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0402-50MG
| InVivoMAb anti-human GPC-2
| 50 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BP0241-5MG
| InVivoPlus anti-mouse IFNAR-1
| 5 mg
| BioXCell
| in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockad
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0384-1MG
| InVivoMAb anti-human GM-CSF
| 1 mg
| BioXCell
| in vitro GM-CSF neutralization, ELISA
|
| Rat
| Human
| Request Quotation
| Request
|
| BP0087-5MG
| InVivoPlus polyclonal Syrian hamster IgG
| 5 mg
| BioXCell
|
|
| Syrian Hamster
|
| Request Quotation
| Request
|
| BE0397-50MG
| InVivoMAb anti-human/mouse GRP78
| 50 mg
| BioXCell
| in vivo GRP78 targeting, in vitro GRP78 targeting,
|
| Mouse
| Human, Mouse
| Request Quotation
| Request
|
| BP0088-100MG
| InVivoPlus rat IgG1 isotype control, anti-horseradish peroxidase
| 100 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BE0403-50MG
| InVivoMAb anti-mouse CD96
| 50 mg
| BioXCell
|
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0004-1-50MG
| InVivoPlus anti-mouse CD8?
| 50 mg
| BioXCell
| in vivo CD8+ T cell depletion, Immunofluorescence,
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0402-1MG
| InVivoMAb anti-human GPC-2
| 1 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BE0412-25MG
| InVivoMAb anti-human GPC3
| 25 mg
| BioXCell
| , ,
|
| Human
|
| Request Quotation
| Request
|
| BE0392-50MG
| InVivoMAb anti-mouse myeloperoxidase (MPO)
| 50 mg
| BioXCell
| in vivo administration, in vitro administration, I
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0407-1MG
| InVivoMAb anti-human Fy3
| 1 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BE0397-1MG
| InVivoMAb anti-human/mouse GRP78
| 1 mg
| BioXCell
| in vivo GRP78 targeting, in vitro GRP78 targeting,
|
| Mouse
| Human, Mouse
| Request Quotation
| Request
|
| BE0402-100MG
| InVivoMAb anti-human GPC-2
| 100 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BP0115-5MG
| InVivoPlus anti-mouse TIM-3 (CD366)
| 5 mg
| BioXCell
| in vivo TIM-3 neutralization, in vitro TIM-3 block
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0060-25MG
| InVivoPlus anti-mouse VEGFR-2
| 25 mg
| BioXCell
| in vivo blocking of VEGF/VEGFR-2 signaling, in vit
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0393-5MG
| InVivoMAb anti-mouse myeloperoxidase (MPO)
| 5 mg
| BioXCell
| in vivo administration, in vitro administration, I
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0175-25MG
| InVivoPlus anti-mouse CD71 (TfR1)
| 25 mg
| BioXCell
| in vivo depletion of CD71+ cells
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0239-50MG
| InVivoPlus anti-mouse 4-1BB (CD137)
| 50 mg
| BioXCell
| in vivo 4-1BB stimulation, in vitro 4-1BB stimulat
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0086-50MG
| InVivoPlus mouse IgG2b isotype control, unknown specificity
| 50 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| BE0412-50MG
| InVivoMAb anti-human GPC3
| 50 mg
| BioXCell
| , ,
|
| Human
|
| Request Quotation
| Request
|
| BE0398-5MG
| InVivoMAb anti-mouse CD83
| 5 mg
| BioXCell
| in vivo CD83 engagement, in vitro CD83 blockade, F
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0131-100MG
| InVivoPlus anti-mouse CTLA-4 (CD152)
| 100 mg
| BioXCell
| in vivo CTLA-4 neutralization, in vitro CTLA-4 neu
|
| Syrian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0380-5MG
| InVivoMAb anti-human c-Kit (CD117)
| 5 mg
| BioXCell
| in vivo c-Kit+ cell depletion, in vitro c-Kit targ
|
| Mouse
| Human
| Request Quotation
| Request
|
| BP0001-1-25MG
| InVivoPlus anti-mouse CD3?
| 25 mg
| BioXCell
| in vivo T cell depletion, in vitro T cell stimulat
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BP0016-2-5MG
| InVivoPlus anti-mouse CD40
| 5 mg
| BioXCell
| in vivo CD40 activation, in vitro B cell stimulati
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0405-100MG
| InVivoMAb anti-human mesothelin
| 100 mg
| BioXCell
| , ,
|
| Rabbit
|
| Request Quotation
| Request
|
| BP0117-5MG
| InVivoPlus anti-mouse CD8?
| 5 mg
| BioXCell
| in vivo CD8+ T cell depletion, Western blot
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0131-5MG
| InVivoPlus anti-mouse CTLA-4 (CD152)
| 5 mg
| BioXCell
| in vivo CTLA-4 neutralization, in vitro CTLA-4 neu
|
| Syrian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0395-25MG
| InVivoMAb anti-mouse/human Mac-2 (Galectin-3)
| 25 mg
| BioXCell
| Western blot, Immunofluorescence, Immunohistochemi
|
| Rat
| Human, Mouse
| Request Quotation
| Request
|
| BE0406-25MG
| InVivoMAb anti-human CD2
| 25 mg
| BioXCell
| , ,
|
| Rat
|
| Request Quotation
| Request
|
| BE0380-50MG
| InVivoMAb anti-human c-Kit (CD117)
| 50 mg
| BioXCell
| in vivo c-Kit+ cell depletion, in vitro c-Kit targ
|
| Mouse
| Human
| Request Quotation
| Request
|
| BP0036-25MG
| InVivoPlus anti-mouse NK1.1
| 25 mg
| BioXCell
| in vivo NK cell depletion, Flow cytometry
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0413-50MG
| InVivoMAb anti-rat TCR ?/?
| 50 mg
| BioXCell
| in vivo administration
|
| Mouse
| Rat
| Request Quotation
| Request
|
| BP0117-50MG
| InVivoPlus anti-mouse CD8?
| 50 mg
| BioXCell
| in vivo CD8+ T cell depletion, Western blot
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0406-100MG
| InVivoMAb anti-human CD2
| 100 mg
| BioXCell
| , ,
|
| Rat
|
| Request Quotation
| Request
|
| BP0086-25MG
| InVivoPlus mouse IgG2b isotype control, unknown specificity
| 25 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| BE0406-1MG
| InVivoMAb anti-human CD2
| 1 mg
| BioXCell
| , ,
|
| Rat
|
| Request Quotation
| Request
|
| BP0017-1-50MG
| InVivoPlus anti-mouse CD40L (CD154)
| 50 mg
| BioXCell
| in vivo blocking of CD40/CD40L signaling, in vitro
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BP0016-2-100MG
| InVivoPlus anti-mouse CD40
| 100 mg
| BioXCell
| in vivo CD40 activation, in vitro B cell stimulati
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0058-100MG
| InVivoPlus anti-mouse TNF?
| 100 mg
| BioXCell
| in vivo TNF? neutralization, in vitro TNF? neutral
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0031-25MG
| InVivoPlus anti-mouse OX40 (CD134)
| 25 mg
| BioXCell
| in vivo OX40 activation, in vitro OX40 activation,
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0003-1-100MG
| InVivoPlus anti-mouse CD4
| 100 mg
| BioXCell
| in vivo CD4+ T cell depletion, Flow cytometry, Wes
|
| Rat
| Mouse
| Request Quotation
| Request
|